Celltrion
셀트리온
Biosimilar and biopharma innovator.
Latest News
Celltrion Files EU Approval for Cosentyx Biosimilar CT-P55
Celltrion has submitted a marketing authorization application to the European Medicines Agency for CT-P55, its biosimilar of Novartis's blockbuster autoimmune drug Cosentyx, as it races to be among the first entrants in a global market worth roughly $6.7 billion.
Celltrion Unveils Novel Drug Pipeline and U.S. Expansion at J.P. Morgan Conference
Celltrion used the 44th J.P. Morgan Healthcare Conference to detail an ambitious pipeline of antibody-drug conjugates and multi-specific antibodies, alongside plans to scale U.S. manufacturing and research to deepen its commitment to the American market.
FDA Clears 300mg Dose of Celltrion's Xolair Biosimilar OMLYCLO
The U.S. FDA has approved a new 300mg strength of Celltrion's OMLYCLO, the first and only interchangeable biosimilar to Xolair, expanding the South Korean drugmaker's immunology portfolio in the United States.
Celltrion's 2025 profit more than doubles on high-margin biosimilars
Celltrion's operating profit surged 137.5% to a record 1.17 trillion won in 2025 as newer, higher-margin biosimilars lifted revenue past the 4 trillion won mark for the first time. The company is pivoting toward profitability and set a 5.3 trillion won revenue target for 2026.
Celltrion's Q2 Operating Profit Surges 77% on Biosimilar Sales
South Korea's Celltrion posted a 77.3% year-on-year jump in second-quarter operating profit, lifted by higher-margin biosimilars and a richer product mix.
Timeline
- Celltrion Files EU Approval for Cosentyx Biosimilar CT-P55
- Celltrion Unveils Novel Drug Pipeline and U.S. Expansion at J.P. Morgan Conference
- FDA Clears 300mg Dose of Celltrion's Xolair Biosimilar OMLYCLO
- Celltrion's 2025 profit more than doubles on high-margin biosimilars
- Celltrion's Q2 Operating Profit Surges 77% on Biosimilar Sales
